Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Howard I. Scher, Karim Fizazi, Fred Saad, +17

New England Journal of Medicine

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, +25

New England Journal of Medicine

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Matthew R. Smith, Karim Fizazi, +22

The Lancet Oncology

UrologyOncologyPrednisone Versus PlaceboAbiraterone AcetateClinical Trials +5

Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

Thomas Wiegel, Dirk Bottke, Ursula Steiner, +17

Journal of Clinical Oncology

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

Matthew R. Smith, Fred Saad, Robert E. Coleman, +18

The Lancet

UrologyOncologyGenitourinary CancerCastration-resistant Prostate CancerCancer Treatment +4

Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma

Annika Schaefer, Monika Jung, Hans‐Joachim Mollenkopf, +7

International Journal of Cancer

Microrna ProfilingPrognostic BiomarkersUrologyOncologyGenitourinary Cancer +11

Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial

Thomas Wiegel, Detlef Bartkowiak, Dirk Bottke, +18

European Urology

UrologySurgical OncologyRadiation MedicineRadiation TherapyMedicine +7

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, +18

European Urology

UrologyOncologyMedicinePharmacotherapyPrevail Study +4

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad, +21

The Lancet Oncology

Era 223UrologyMedicineClinical TrialsPharmacotherapy +6

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Fred Saad, Joan Carles, Silke Gillessen, +11

The Lancet Oncology

UrologySingle-arm Phase 3BGenitourinary CancerMedicineClinical Trials +7